Fig. 7

UCMSCs-exo/eNOS promote angiogenesis and chronic wound healing through multiple cascade reactions and molecular activation. I: Treatment with PBS. II: Treatment with UCMSCs-exo. III: Treatment with UCMSCs-exo/eNOS. a qRT-PCR analysis of the mRNA expression of angiogenesis-associated and healing-associated factors. b Western blot analysis of HIF-1α, Ang2, VEGFA, bFGF, and Ang1 protein expression in the wounds of each group up to day 21 of treatment. c, d, e, f, g Quantitative analysis of HIF-1α, Ang2, VEGFA, bFGF, and Ang1 expression. h Western blot analysis of p-FAK, p-ERK1/2, p-PI3K, p-Akt, and p-mTOR protein expression in wounds of each group at day 21 of treatment. i, j, k, l, m Quantitative analysis of the phosphorylation of p-FAK, p-ERK1/2, p-PI3K, p-Akt, and p-mTOR. n Western blot analysis of p-STAT3 and p-Smad3 expression in the wounds of each group at day 21 of treatment. o, p, Quantitative analysis of the degree of phosphorylation of p-STAT3 and p-Smad3. q Western blot analysis of the protein expression of SIRT3, SIRT1, FoxO1, FoxO3a, and LC3 in the wounds of each group at day 21 of treatment. r, s, t, u, v Quantitative analysis of SIRT3, SIRT1, FoxO1, FoxO3a, and LC3-II. Results are from at least three independent replicate experiments. Data represent means ± SD. *p < 0.05, **p < 0.01, ***p < 0.001 vs. PBS group; ^#p < 0.05, ^##p < 0.01, ^###p < 0.001 vs. UCMSCs-exo group as determined by two-tailed t-tests